<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 22, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487199</url>
  </required_header>
  <id_info>
    <org_study_id>M15-461</org_study_id>
    <secondary_id>2015-002012-33</secondary_id>
    <nct_id>NCT02487199</nct_id>
  </id_info>
  <brief_title>Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease</brief_title>
  <official_title>An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Spain: Ministry of Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Australia: National Health and Medical Research Council</authority>
    <authority>New Zealand: Ministry of Health</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of ombitasvir/paritaprevir/ritonavir with or
      without dasabuvir in adult genotype 1a or genotype 4 hepatitis C infected participants with
      severe kidney impairment or end-stage kidney disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of participants with SVR12 in each arm</measure>
    <time_frame>12 weeks after last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (&lt; LLOQ) 12 weeks after the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Screening until 30 days after last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with on-treatment virologic failure in each treatment</measure>
    <time_frame>Up to 12 weeks after first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>On-treatment virologic failure is defined as quantifiable hepatitis C virus ribonucleic acid(HCV RNA) throughout the entire treatment period with at least 6 weeks of treatment, confirmed greater than the lower limit of quantification HCV RNA after previously having unquantifiable HCV RNA, or a confirmed increase from nadir of at least one log10 in HCV RNA during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with post-treatment relapse within 12 weeks following end of treatment in each arm</measure>
    <time_frame>Up to 12 weeks after last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Virologic relapse after treatment is defined as confirmed plasma hepatitis C virus ribonucleic acid (HCV RNA) &gt; the lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA &lt; LLOQ at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HCV</condition>
  <condition>Genotype 1a</condition>
  <condition>Genotype 4</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Genotype 1a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with 3-DAA regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with 2-DAA regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir/Paritaprevir/Ritonavir</intervention_name>
    <arm_group_label>Genotype 1a</arm_group_label>
    <arm_group_label>Genotype 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasabuvir</intervention_name>
    <arm_group_label>Genotype 1a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: -Chronic hepatitis C, genotype 1a infection or genotype 4 infection
        (HCV RNA level greater than 1,000 IU/mL at Screening).

          -  Females must be post-menopausal, of non-child bearing potential or practicing
             specific forms of birth control.

          -  Chronic kidney disease stage 4 or stage 5.

        Exclusion Criteria: - Females who are pregnant or breastfeeding

          -  Positive screen for hepatitis B Surface antigen or anti-Human Immunodeficiency virus
             antibody

          -  HCV genotype performed during screening unable to genotype or co-infection with any
             other HCV genotype, no mixed genotypes.

          -  Abnormal laboratory tests

          -  Current enrollment in another investigational study

          -  Previous or current treatment with a direct acting antiviral agent (DAA) containing
             regimen

          -  Any evidence of liver cirrhosis or liver cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Cohen, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Rodecki</last_name>
    <phone>847-937-6009</phone>
    <email>anna.rodecki@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabriele Schaefer</last_name>
    <phone>+49 621-589-2608</phone>
    <email>gabriele.schaefer@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141184</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141184, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141183</name>
      <address>
        <city>Herston</city>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141183, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141182</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141182, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141181</name>
      <address>
        <city>Randwick</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141181, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141180</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141180, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141179</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141179, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141178</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141178, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141177</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141177, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 140973</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 140973, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141176</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141176, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 20, 2015</lastchanged_date>
  <firstreceived_date>June 29, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C infection</keyword>
  <keyword>hepatitis C</keyword>
  <keyword>severe kidney disease</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
